Editorial & Columns Inflation and Pharmaceutical Products: A Global Concern May 22, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Skin in the Game: Promoter Holding in Indian Pharmaceutical Companies May 15, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns India-Australia Economic Cooperation and Trade Agreement & Pharmaceutical Exports from India May 9, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Pharma 2.0: Indian Pharmaceutical Companies strive to Create & Enhance Strength in Biopharmaceuticals May 2, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Patent Expiry & Innovator Pharmaceutical Companies : Mechanisms applied to preserve market dominance April 24, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Drivers of Business Growth : Evidence from Indian Pharmaceutical Industry April 18, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Prescription for Segment Reporting by Pharmaceutical Companies in India April 13, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Foreign Direct Investment and Pharmaceutical Industry in India April 5, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Third Generation Curse : Caution & Survival Lessons for family-owned Pharmaceutical Companies in India March 14, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Private Equity and Indian Pharmaceutical Industry- A Review March 7, 2024 | Dr. Anil Kumar Angrish | No Comments | More